+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

O

Actively Recruiting

This research aims to evaluate the pharmacokinetics, safety, and tolerability of AX251 long-acting injectable LAI given as a single dose in adults with schizophrenia. The study focuses on different dose levels of AX251 LAI through sequential dose-escalation groups to understand how the drug is processed and tolerated. It is a Phase 1, open-label, multicenter trial sponsored by Anxo Pharmaceutical Co., Ltd. Participants will receive one of four doses of AX251 LAI45 mg, 90 mg, 135 mg, or 180 mgin separate groups. The study is non-randomized and does not use blinding. Each participant will receive a single injection of the assigned dose and be monitored over time. There are no placebo groups, and the primary treatment period involves only one dose administration. During the study, participants will be closely monitored with blood sampling for pharmacokinetic measurements at multiple times from immediately before dosing up to 70 days after injection. Safety will be assessed by tracking adverse events from baseline through Day 70. Participants must stay at the study site for 7 days after dosing for observation and will undergo clinical evaluations, including physical exams, ECGs, and laboratory tests. The total participation lasts about 10 weeks, focusing on safety and drug behavior in the body.

Age: 18Years - 65YearsAll GendersPhase 1
4 locations
G

Actively Recruiting

Researchers are investigating the use of lisaftoclax combined with BTK inhibitors in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma CLLSLL who have previously been treated with BTK inhibitors. This global, open-label, phase III study aims to evaluate the effectiveness and safety of this combination compared to BTK inhibitor alone in patients who have been on BTK inhibitor monotherapy for at least 12 months. About 440 participants will be randomly assigned to one of two groups one will receive lisaftoclax together with a BTK inhibitor, and the other will receive only a BTK inhibitor. The study uses a parallel design where participants are allocated equally to each treatment arm to compare outcomes clearly. Both treatments are administered under medical supervision, and the study is open-label, meaning both the researchers and participants know which treatment is given. Participants will be assessed regularly over the course of the study, with evaluations including disease progression measured at 12 months and overall survival also tracked at 12 months. Eligibility screening includes assessments of performance status, bone marrow, kidney, and liver function, as well as consent to follow the study schedule. The research team monitors safety and treatment effects throughout the trial, which is expected to complete by late 2027.

Age: 18Years - 99YearsAll GendersPhase 3
135 locations
P

Actively Recruiting

Researchers are evaluating ISB 2001 in adults with relapsed or refractory multiple myeloma RR MM who have already been treated with immunomodulatory drugs, proteasome inhibitors, and anti-CD38 therapies but remain resistant or intolerant to these treatments. This first-in-human, Phase 1, open-label study aims to assess the safety and anti-myeloma activity of ISB 2001. The study is sponsored by Ichnos Sciences SA and involves participants who have measurable disease and adequate organ function. The study has two parts dose escalation and dose expansion. In the dose escalation phase, participants receive increasing doses of ISB 2001 to determine the maximum safe dose. In the dose expansion phase, participants receive ISB 2001 at the optimal dose identified to further confirm safety and biological activity. ISB 2001 is given weekly on Days 1, 8, 15, and 22 of each 28-day cycle, with an additional step-up dose on Day 4 of Cycle 1. Treatment continues until disease progression, unacceptable side effects, or withdrawal. Participants will undergo regular monitoring for treatment-emergent adverse events and dose-limiting toxicities during the first cycle, with follow-up visits extending up to 18 months. Researchers will measure drug levels in the blood, immune responses to the drug, and multiple clinical outcomes related to disease response and progression. Ongoing assessments will include physical exams, performance status, and laboratory tests to track safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 1
32 locations